TICKERNERD
Menu
RLYBRLYBHealthcare · Biotechnology

RLYB Stock Forecast: Rallybio Corp. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$15
−3.63% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 28 Oct 2026 — in the upper half.

Market cap
$84.6M
Ticker Nerd rank
60/ 100
Median analyst target
—
Analysts covering
1
Revenue$0.0−100.0% y/y
Operating income−$5.7M
Net income$43.7M
Free cash flow$45.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.0%
1M
−10.5%
YTD
+180.8%
1Y
+218.4%
From 52W high
−10.5%
From 52W low
+255.9%
$4
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RLYB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rallybio Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
60/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Quality
89
Size
75
Issuance
58
Accruals
55
Growth
50
Volatility
40
Revisions
25
Value
19

Momentum (99): The shares have been drifting up relative to others.

Value (19): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RLYB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RLYB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15Jan 26Apr 26Jul 26Oct 26RLYB

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Apr 2025Jones TradingDowngradeHold—
9 Apr 2025HC Wainwright & Co.DowngradeNeutral—
17 Mar 2025HC Wainwright & Co.ReiteratesBuy—
12 Feb 2025HC Wainwright & Co.ReiteratesBuy—
13 Jan 2025HC Wainwright & Co.ReiteratesBuy—
3 Dec 2024HC Wainwright & Co.ReiteratesBuy—
22 Nov 2024HC Wainwright & Co.ReiteratesBuy—
8 Nov 2024HC Wainwright & Co.MaintainsBuy—
30 Oct 2024HC Wainwright & Co.ReiteratesBuy—
1 Oct 2024HC Wainwright & Co.ReiteratesBuy—
3 Sept 2024HC Wainwright & Co.ReiteratesBuy—
26 Aug 2024Evercore ISI GroupMaintainsOutperform—
12 Aug 2024HC Wainwright & Co.MaintainsBuy—
15 May 2024JP MorganDowngradeNeutral—
10 May 2024HC Wainwright & Co.ReiteratesBuy—
19 Apr 2024JMP SecuritiesReiteratesMarket Outperform—
18 Apr 2024JMP SecuritiesReiteratesMarket Outperform—
11 Apr 2024WedbushMaintainsOutperform—
13 Mar 2024HC Wainwright & Co.MaintainsBuy—
13 Mar 2024JMP SecuritiesReiteratesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

RLYB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RLYB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Rallybio Corp. returned +218.4% against +13.1% for the S&P 500, dividends included.

RLYB vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300350400Jan 26Apr 26Jul 26Oct 26RLYBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RLYB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Rallybio Corp. (RLYB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.5×

Cheaper than 67% of US stocks

Price / sales
133.8×

Cheaper than 3% of US stocks

Price / book
1.5×

Cheaper than 54% of US stocks

EV / EBITDA
0.3×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−3935.4%

Higher than 3% of US stocks

Net margin
7051.2%

Higher than 99% of US stocks

Returns & dividend
Return on equity
64.9%

Higher than 94% of US stocks

Return on assets
−21.3%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Rallybio Corp. (RLYB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rallybio Corp. has a market value of $84.6M and an enterprise value of −$8.3M.

  • Revenue in the twelve months to 30 June 2026: $646K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: $45.6M, a 7051.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $26.7M.

  • Shares outstanding: 5.3M.

  • Trailing P/E: 3.5×; forward P/E: −3.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Rallybio Corp. employs 7 people — $92K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

RLYB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RLYBRallybio Corp.$84.6M60
RANIRani Therapeutics Holdings, Inc.$83.9M73
ATRAAtara Biotherapeutics, Inc.$86.9M58
NTHINeOnc Technologies Holdings, Inc.$87.3M20
CNXUConexeu Sciences, Inc.$88.8M1
EQEquillium, Inc.$89.8M37
CRBPCorbus Pharmaceuticals Holdings, Inc.$78.7M18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rallybio Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RLYB news & analysis

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

Business Wire · 22 Oct 2026neutral

Kahn Swick & Foti, LLC is investigating Rallybio’s proposed merger with Avenzo Therapeutics, including the merger terms and the process leading to it. Rallybio’s pre-transaction equityholders are expected to own approximately 2.8% of the combined company upon completion.

Why it matters — The investigation concerns the proposed transaction and its terms, which are relevant to RLYB shareholders following the merger process.

FAQ

Frequently asked questions about RLYB stock

Is RLYB stock a buy right now?

Of the 1 analysts covering Rallybio Corp., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rallybio Corp. 60 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RLYB?

As at 28 Oct 2026, Rallybio Corp. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

What is the RLYB stock forecast for 2030?

No analyst covering Rallybio Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RLYB are extrapolating price history, which says nothing about the business.

How has RLYB stock performed over the past year?

Rallybio Corp. returned +218.4% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rallybio Corp. do?

Rallybio Corp. is a clinical-stage biotechnology company focused on developing and commercializing therapies for severe and rare diseases.

What is the latest news on RLYB?

The most recent item we track (Business Wire, 22 Oct 2026): "Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB". Kahn Swick & Foti, LLC is investigating Rallybio’s proposed merger with Avenzo Therapeutics, including the merger terms and the process leading to it. Rallybio’s pre-transaction equityholders are expected to own approximately 2.8% of the combined company upon completion.

Company

About Rallybio Corp.

Rallybio Corp. is a clinical-stage biotechnology company focused on developing and commercializing therapies for severe and rare diseases. The company’s current pipeline centers on areas such as complement dysregulation, hematology, maternal-fetal health, and iron overload disorders. Its lead programs include RLYB116, a complement component 5 inhibitor being developed for diseases driven by complement dysregulation, and RLYB332, a preclinical antibody candidate for iron overload-related conditions. Rallybio also works on therapies for rare maternal-fetal disorders, reflecting its emphasis on areas with significant unmet medical need. Headquartered in New Haven, Connecticut, Rallybio operates as a focused drug development company in the biotechnology sector, advancing specialized treatments designed for patients with serious, underserved conditions.

CEO Dr. Stephen Uden M.D., MBBS · 7 employees · United States · https://www.rallybio.com